Can bioavailability of low-variance drugs be estimated with an unpaired, sparse sampling design?

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 4, 1998, Pages 437-443

  Wright, Peter M C ^b   Fisher, Dennis M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISATRACURIUM;

AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; MODEL; PRIORITY JOURNAL; SIMULATION;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; HUMANS; INJECTIONS, INTRAVENOUS; MODELS, STATISTICAL; RESEARCH DESIGN; SAMPLE SIZE;

EID: 0031946029     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90039-X     Document Type: Article

References (6)

1. Reynolds LM, Lau M, Brown R, Luks A, Fisher DM. Intramuscular rocuronium in infants and children. Doseranging and tracheal intubating conditions. Anesthesiology 1996;85:231-9.
2. Sorooshian SS, Stafford MA, Eastwood NB, Boyd AH, Hull CJ, Wright PMC. Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. Anesthesiology 1996;84:1083-91.
3. Moore E, Faix R, Banagale R, Grasela T. The population pharmacokinetics of theophylline in neonates and young infants. J Pharmacokinet Biopharm 1989;17:47-66.
4. Thomson AH, Way S, Bryson SM, McGovern EM, Kelman AW, Whiting B. Population pharmacokinetics of gentamicin in neonates. Dev Pharmacol Ther 1988;11:173-9.
5. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993;21:735-50.
6. Kisor DF, Schmith VD, Wargin WA, Lien CA, Ornstein E, Cook DR. Importance of the organ-independent elimination of cisatracurium. Anesth Analg 1996;83:1065-71.